Trial is evaluating VIPER-101, a novel, gene edited, autologous dual-population CAR-T therapy in patients with T-cell ...

SOUTH SAN FRANCISCO, CA, USA I May 27, 2025 I Circle Pharma, a clinical-stage biopharmaceutical company advancing macrocycle therapeutics for ...

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and ...

The Bioinformatics department under Agricultural Engineering and Technology Faculty of Bangladesh Agriculture University (BAU ...

dose limiting toxicity dose level has not been identified in doses up to 250 mg/day Preclinical posters strengthen the NXP900 clinical development strategy as single agent in biomarker-targeted ...

FBLG READ THE FULL FBLG RESEARCH REPORT Business Update Preclinical Psoriasis Data Presented at SID Annual Meeting On May 16, 2025, FibroBiologics, Inc. (NASDAQ:FBLG) announced a poster presentation ...

Dr. David Bingaman, Chief Development Officer ... of clinical and preclinical trial endpoint and technology services, will be presenting a poster at the Association for Research in Vision and ...

While advancements in VR technology have improved user engagement, existing systems often inadequately integrate vibrotactile and kinesthetic feedback with auditory and visual elements, limiting the ...

a provider of preclinical development services. Utilizing its proprietary CAB platform technology, BioAtla develops novel, reversibly active monoclonal and bispecific antibodies and other protein ...

REDWOOD CITY, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced that preliminary clinical ...

today announced its abstract has been selected for a poster presentation at the 2025 European Hematology Association Annual Meeting (EHA) being held June 12-15 in Milan, Italy. The abstract ...